Endocrinology
| Study name | Study Title | Study Type | Sponsor | Sponsor Type |
|---|---|---|---|---|
| Redefine 2 | "Efficacy and safety of cagrilintide s.c. 2.4 mg in combination with semaglutide s.c. 2.4 mg (CagriSema s.c. 2.4 mg/2.4 mg) once-weekly in participants with overweight or obesity and type 2 diabetes" | Clinical Trial (NCT05394519) | Novo Nordisk | Commercial: Industry |